Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Salestools Logo

Salestools

Der #1 KI-Agent für Vertriebsteams und Go-to-Market-Teams. Verkaufen Sie mehr, schneller, mit weniger Aufwand.

Produkt

  • KI-Vertriebsagenten
  • Intent-Daten
  • Technologiedaten
  • Besucher-Tracking
  • Co-Pilot
  • Social Selling

Lösungen

  • Kundenservice
  • E-Commerce
  • SaaS
  • Enterprise
  • Kleinunternehmen

Ressourcen

  • Der Report
  • Dokumentation
  • API-Referenz
  • Hilfecenter
  • Blog
  • Fallstudien
  • Webinare

Unternehmen

  • Über uns
  • Karriere
  • Presse
  • Kontakt
  • Partner

Unsere Standorte

  • New York, HQ
  • Bukarest, KI-Forschungslabor
  • Zug, Schweiz

© 2026 Salestools. Alle Rechte vorbehalten.

Datenbedingungen & SicherheitDatenschutzerklärungNutzungsbedingungenAcceptable Use
Alle Systeme betriebsbereit
Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Back to Reports
Fundraising

Astranis

Astranis Raises $200M in Series D

1641 N California Boulevard, Walnut Creek, CA 94596April 9, 20242 min read
Employees
400+

Astranis Raises $200M in Series D


Astranis has successfully raised $200M in a Series D at a $1.4B valuation led by Andreessen Horachi, Venrock, BlackRock, Fidelity, Baillie Gifford.


Company Overview


Astranis is a Aerospace company headquartered in 1641 N California Boulevard, Walnut Creek, CA 94596, founded in 2015 with 400+ employees.


Satellite communications company


Fundraising Details


  • Amount Raised: $200M
  • Round Type: Series D
  • Valuation: $1.4B
  • Date: 2024-04-09
  • Investors: Andreessen Horachi, Venrock, BlackRock, Fidelity, Baillie Gifford

About Astranis


Satellite communications company The company is positioned in the Aerospace sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 1641 N California Boulevard, Walnut Creek, CA 94596
  • Founded: 2015
  • Team Size: 400+
  • Industry: Aerospace

What This Means


This funding round demonstrates strong investor confidence in Astranis's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Aerospace sector continues to attract significant investment as companies innovate to meet evolving market demands. Astranis's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $1.4B valuation marks an important milestone for Astranis, positioning the company among notable players in the Aerospace industry.


Looking Ahead


With this new capital, Astranis is well-positioned to execute on its growth strategy and continue building innovative solutions in the Aerospace space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-04-09. For more information about Astranis, visit their headquarters at 1641 N California Boulevard, Walnut Creek, CA 94596.

Company Info

Headquarters
1641 N California Boulevard, Walnut Creek, CA 94596
Founded
2015
Team Size
400+

Topics

Fundraising(2912)Aerospace(308)Series D(267)Astranis

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free